The nuclear proliferation biomarker Ki-67 has multiple potential roles in breast and other cancers, both as a prognostic but also predictive marker. However, several studies have shown that the assessment of Ki-67 with immunohistochemistry (IHC) suffers from both intra-and inter-observer variability and low reproducibility. On top of that it is still being debated what the most appropriate way of scoring Ki-67 IHC is - should one use global scoring or the hot spot scoring method? In this webinar we will look into how Visiopharm CE-IVD APPs can be used for standardizing the assessment of Ki-67 IHC. We will also show how the APPs can accommodate both the global scoring method and the hot spot scoring method allowing for a tailored solution that fits the diagnostic workflow in your laboratory. We will focus on the clinically validated APPs, but will also reveal some of the AI technologies we have for research use.
1. Understand the limitations of manual biomarker assessment in image analysis
2. Learn how CE-IVD APPs can used for standardization of Ki-67 scoring
3. Get a glimpse of the future AI-powered workflows for biomarker analysis